Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

Reducing Disparities in Late Life Depression and Metabolic Syndrome
BRIGHTEN Heart: Reducing Disparities in Late Life Depression and Metabolic Syndrome
Status: Enrolling
Updated:  1/24/2014
Cook County Health and Hospital System
mi
from
Chicago, IL
Reducing Disparities in Late Life Depression and Metabolic Syndrome
BRIGHTEN Heart: Reducing Disparities in Late Life Depression and Metabolic Syndrome
Status: Enrolling
Updated: 1/24/2014
Cook County Health and Hospital System
mi
from
Chicago, IL
Click here to add this to my saved trials
Reducing Disparities in Late Life Depression and Metabolic Syndrome
BRIGHTEN Heart: Reducing Disparities in Late Life Depression and Metabolic Syndrome
Status: Enrolling
Updated:  1/24/2014
Resurrection Medical Center
mi
from
Chicago, IL
Reducing Disparities in Late Life Depression and Metabolic Syndrome
BRIGHTEN Heart: Reducing Disparities in Late Life Depression and Metabolic Syndrome
Status: Enrolling
Updated: 1/24/2014
Resurrection Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Chander, AZ
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Chander, AZ
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Phoenix, AZ
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
West Hills, CA
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
West Hills, CA
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Doral, FL
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Doral, FL
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Jacksonville, FL
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Miami, FL
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Chicago, IL
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Evansville, IN
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Evansville, IN
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Indianopolis, IN
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Indianopolis, IN
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Overland Park, KA
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Louisville, KY
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Auburn, ME
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Auburn, ME
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Bethesda, MD
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Methuen, MA
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Methuen, MA
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Trenton, NJ
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Trenton, NJ
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Rochester, NY
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Raleigh, NC
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Cincinnati, OH
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Tulsa, OK
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Penndel, PA
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Penndel, PA
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Greensboro, SC
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Greensboro, SC
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Dallas, TX
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Houston, TX
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Salt Lake City, UT
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Norfolk, VA
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated:  3/14/2014
Clinical Research Facility
mi
from
Richmond, VA
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Status: Enrolling
Updated: 3/14/2014
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers
Status: Enrolling
Updated:  4/10/2014
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers
Status: Enrolling
Updated: 4/10/2014
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (Aged 6 to <18 Years) With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Minneapolis, MN
A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (Aged 6 to <18 Years) With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of Pf-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated:  1/12/2015
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of Pf-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated: 1/12/2015
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of Pf-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated:  1/12/2015
Miami Research Associates
mi
from
South Miami, FL
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of Pf-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated: 1/12/2015
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of Pf-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated:  1/12/2015
MRA Clinical Research, LLC
mi
from
South Miami, FL
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of Pf-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated: 1/12/2015
MRA Clinical Research, LLC
mi
from
South Miami, FL
Click here to add this to my saved trials
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of Pf-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated:  1/12/2015
Vince and Associates Clinical Research
mi
from
Overland Park, KA
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of Pf-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated: 1/12/2015
Vince and Associates Clinical Research
mi
from
Overland Park, KA
Click here to add this to my saved trials
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of Pf-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated:  1/12/2015
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of Pf-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated: 1/12/2015
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Hypertrophic Regression With N-Acetylcysteine in HCM
Pilot Feasibility Study With N-acetylcystein (NAC) in Patients With HCM Caused by Sarcomere Proteins Mutations
Status: Enrolling
Updated:  5/26/2015
UTHSC
mi
from
Houston, TX
Hypertrophic Regression With N-Acetylcysteine in HCM
Pilot Feasibility Study With N-acetylcystein (NAC) in Patients With HCM Caused by Sarcomere Proteins Mutations
Status: Enrolling
Updated: 5/26/2015
UTHSC
mi
from
Houston, TX
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Auburn, ME
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Auburn, ME
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Miami, FL
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated:  7/28/2015
Clinical Research Facility
mi
from
Hartford, CT
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated: 7/28/2015
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated:  7/28/2015
Clinical Research Facility
mi
from
N. Massapequa, NY
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated: 7/28/2015
Clinical Research Facility
mi
from
N. Massapequa, NY
Click here to add this to my saved trials
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated:  7/28/2015
Clinical Research Facility
mi
from
Chicoutimi,
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated: 7/28/2015
Clinical Research Facility
mi
from
Chicoutimi,
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
New York, NY
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Anaheim, CA
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Beverly Hills, CA
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Mission Viejo, CA
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Newport Beach, CA
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Northridge, CA
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Northridge, CA
Click here to add this to my saved trials